Lexicon Pharmaceuticals

Small-molecule therapeutics

LXRX · Nasdaq · United States

Share price · LXRX

$1.72-0.70 (-28.93%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.0M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LXRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+10.6%
  2. 9 Oct 2026-4.5%
  3. 24 Sep 2026-9.7%
  4. 30 Jun 2026-9.1%
  5. 26 Jun 2026+11.4%
  6. 11 May 2026+15.5%
  7. 8 May 2026+19.0%
  8. 19 Feb 2026+15.2%
  9. 10 Feb 2026+9.2%

    Nothing announced by LXRX that day or the session before.

  10. 30 Jan 2026-19.4%

Share of unusual movement by asset

For each asset, the share of LXRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Sotagliflozin (Inpefa) (Inpefa)
events and moves
82%
Other company news (earnings, financing, releases naming no asset)—32%
Sessions with no dated event—66%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
SGLT1/2 (dual)Small molecule
Heart FailureChronic Kidney DiseaseType 1 DiabetesHypertrophic Cardiomyopathy
Phase 2
AP2-associated kinase 1 (AAK1)Small molecule
Diabetic Peripheral Neuropathic Pain

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Sotagliflozin (Inpefa)Phase 3Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Est. primary completion 2027-01 · NCT06481891 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$11M$16M$44M+ $139M short-term inv.$14M-$8.1M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.7M$17M$41M+ $150M short-term inv.$32M-$9.2M operating cash flowreport ↗
2026-Q1$21M$13M$67M+ $133M short-term inv.$1.0M-$15M operating cash flowreport ↗
2025-Q3$14M$19M$79M+ $66M short-term inv.$13M-$24M operating cash flowreport ↗
2025-Q2$29M$16M$50M+ $118M short-term inv.—$17M operating cash flowreport ↗
2025-Q1$1.3M$15M$63M+ $132M short-term inv.$25M-$44M operating cash flowreport ↗
2024-Q3$1.8M$26M$35M+ $224M short-term inv.$65M-$54M operating cash flowreport ↗
2024-Q2$1.6M$18M$36M+ $274M short-term inv.$53M-$49M operating cash flowreport ↗
2024-Q1$1.1M$14M$96M+ $259M short-term inv.$48M-$55M operating cash flowreport ↗
2023-Q3$0.2M$18M$21M+ $197M short-term inv.$51M-$42M operating cash flowreport ↗
2023-Q2$0.3M$15M$102M+ $154M short-term inv.$45M-$38M operating cash flowreport ↗
2023-Q1<$0.1M$12M$26M+ $80M short-term inv.$32M-$32M operating cash flowreport ↗
2022-Q3<$0.1M$11M$19M+ $117M short-term inv.$23M-$19M operating cash flowreport ↗
2022-Q2<$0.1M$13M$21M+ $41M short-term inv.$25M-$24M operating cash flowreport ↗
2022-Q1—$15M—+ $27M short-term inv.$23M-$23M operating cash flowreport ↗
2021-Q3<$0.1M$16M—+ $29M short-term inv.$23M-$17M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$50M$61M$63M+ $62M short-term inv.$13M-$68M operating cash flowreport ↗

Lexicon Pharmaceuticals reported full-year 2025 revenue of $49.8M, up 60.2% YoY, with R&D spend of $61.12M, down 27.7% YoY. The company ended the year with $63.33M in cash and equivalents, or $125.2M including investments and restricted cash, and reported a net loss of $50.34M for the full year.

Lexicon stated that pivotal sotagliflozin milestones remain on schedule, including NDA resubmission in type 1 diabetes and enrollment completion of the SONATA-HCM Phase 3 study in mid-2026, with topline results expected in the first quarter of 2027; the study had surpassed 50% enrollment across 130 sites. A positive End-of-Phase 2 meeting with the FDA supports Phase 3 readiness for pilavapadin in diabetic peripheral neuropathic pain, and partnership discussions continue. The company also completed IND-enabling activities for LX9851, received a $10M milestone payment from Novo Nordisk in February 2026, and raised approximately $96.7M in net proceeds from a stock sale.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$31M$84M$67M+ $171M short-term inv.$50M-$179M operating cash flowreport ↗
2023-FY$1.2M$59M$22M+ $148M short-term inv.$44M-$162M operating cash flowreport ↗
2022-FY$0.1M$53M$46M+ $92M short-term inv.$25M-$89M operating cash flowreport ↗
2021-FY$0.3M$55M$64M+ $23M short-term inv.$22M-$87M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 9 purchases ($2.8M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06Exton Michael · director, Chief Executive OfficerOpen-market purchase30,064$1.66$50KForm 4
2026-06-03DEBBANE RAYMOND · directorOption exercise89,312——Form 4
2026-06-03Amouyal Philippe · directorOption exercise89,312——Form 4
2026-06-03BARKER SAM L · directorOption exercise89,312——Form 4
2026-06-03Cheung Ivan · directorOption exercise89,312——Form 4
2026-06-03SOBECKI CHRISTOPHER J · directorOption exercise89,312——Form 4
2026-06-03Sullivan Diane E. · directorOption exercise89,312——Form 4
2026-06-03Swain Judith L · directorOption exercise89,312——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 136 reporting institutions held 323.4M shares ($502.1M, 72.6% of shares outstanding).

#InstitutionSharesValue
1Artal Group S.A.154,734,327$241.4M
2FMR LLC45,056,338$70.3M
3Siren, L.L.C.44,303,518$69.1M
4Sessa Capital IM, L.P.17,912,961$27.9M
5VANGUARD CAPITAL MANAGEMENT LLC9,519,167$14.8M
6Point72 Asset Management, L.P.7,814,606$12.2M
7MILLENNIUM MANAGEMENT LLC4,944,731$7.7M
8BlackRock, Inc.3,322,219$5.2M
9GEODE CAPITAL MANAGEMENT, LLC3,169,111$4.9M
10JANE STREET GROUP, LLC2,665,938$4.2M
11UBS Group AG2,483,182$3.9M
12MARSHALL WACE, LLP2,376,304$3.7M
13SUSQUEHANNA INTERNATIONAL GROUP, LLP2,121,164$3.3M
14CIBC Bancorp USA Inc.1,800,000$2.8M
15RENAISSANCE TECHNOLOGIES LLC1,600,500$2.5M